Literature DB >> 7688950

Baseline and early natural history report. The Central Vein Occlusion Study.

.   

Abstract

OBJECTIVES: To evaluate panretinal photocoagulation for ischemic central vein occlusion and macular grid-pattern photocoagulation for macular edema with reduced visual acuity due to central vein occlusion and to further define the natural history of central vein occlusion.
DESIGN: A multicenter randomized controlled clinical trial supported by the National Eye Institute, Bethesda, Md. PATIENTS: A total of 728 eyes from 725 patients were entered into one or more of four study groups: perfused, nonperfused, indeterminate perfusion, and macular edema.
RESULTS: Follow-up of study patients is still in progress and no results are available for the randomized groups (nonperfused and macular edema). Thirty-eight (83%) of 46 evaluable eyes in the indeterminate group eventually demonstrated at least 10 disc areas of nonperfusion (28 eyes) or developed iris and/or angle neovascularization before retinal status could be determined (10 eyes). Four-month follow-up information is available for 522 of the 547 eyes in the perfused group. Thirty of these 522 eyes demonstrated iris and/or angle neovascularization at or before the 4-month follow-up visit. An additional 51 eyes had developed evidence of at least 10 disc areas of nonperfusion by the time of the 4-month visit.
CONCLUSIONS: These findings confirm the importance of frequent follow-up examinations, including undilated slit-lamp examination of the iris, and gonioscopy in the management of all patients with recent onset of central vein occlusion.

Entities:  

Mesh:

Year:  1993        PMID: 7688950     DOI: 10.1001/archopht.1993.01090080083022

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  77 in total

Review 1.  The management of retinal vein occlusion: is interventional ophthalmology the way forward?

Authors:  H Shahid; P Hossain; W M Amoaku
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

2.  Laser induced chorioretinal venous anastomosis in ischaemic central retinal vein occlusion.

Authors:  A K H Kwok; V Y W Lee; T Y Y Lai; C Hon
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

3.  Natural history of visual outcome in central retinal vein occlusion.

Authors:  Sohan Singh Hayreh; Patricia A Podhajsky; M Bridget Zimmerman
Journal:  Ophthalmology       Date:  2010-08-17       Impact factor: 12.079

Review 4.  Central retinal vein occlusion: modifying current treatment protocols.

Authors:  M Ashraf; A A R Souka; R P Singh
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

5.  Early chorioretinal anastomosis in non-ischaemic CRVO: a randomised trial.

Authors:  R J Antcliff; E J Mayer; T H Williamson; J S Shilling
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

Review 6.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

7.  [Ultra-widefield angiography for retinal vein occlusion : How large is large enough?]

Authors:  M Storch; S Bemme; M Rehak; H Hoerauf; N Feltgen
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

8.  Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.

Authors:  Alexander Rouvas; Petros Petrou; Ioannis Vergados; Dimitrios Pechtasides; Vasilios Liarakos; Maria Mitsopoulou; Ioannis Ladas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-16       Impact factor: 3.117

Review 9.  [Retinal vein occlusions].

Authors:  S Dithmar; L L Hansen; F G Holz
Journal:  Ophthalmologe       Date:  2003-07       Impact factor: 1.059

10.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.